An engineered construct combining complement regulatory and surface-recognition domains represents a minimal-size functional factor H

Journal of Immunology

Volumn 191, Issue 2, 2013, Pages 912-921

  Hebecker, Mario ^a   Alba Domínguez, María ^b,c   Roumenina, Lubka T ^d,e,f   Reuter, Stefanie ^a   Hyvar̈inen, Satu ^g   Dragon Durey, Marie Agnès ^d,e,f,h   Sakari Jokiranta, T ^g   Sańchez Corral, Pilar ^b,c   Józsi, Mihaĺy ^a,i  

^a HANS KNÖLL INSTITUTE   (Germany)

^b HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d CENTRE DE RECHERCHE DES CORDELIERS   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g UNIVERSITY OF HELSINKI   (Finland)

^h HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

ⁱ EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; EPITOPE; MALONALDEHYDE; PENTRAXIN 3; RECOMBINANT COMPLEMENT FACTOR H; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPLEMENT DEPOSITION; COMPLEMENT DISORDER; COMPLEMENT INHIBITION; CONTROLLED STUDY; CYTOLYSIS; DRUG PROTEIN BINDING; DRUG STRUCTURE; EXTRACELLULAR MATRIX; HOST CELL; HUMAN; HUMAN CELL; IMMUNE DYSREGULATION; IMMUNOREGULATION; IN VITRO STUDY; MOLECULAR RECOGNITION; MOLECULAR SIZE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY;

AMINO ACID SEQUENCE; BASE SEQUENCE; C-REACTIVE PROTEIN; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; MALONDIALDEHYDE; PROTEIN BINDING; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; SEQUENCE ANALYSIS, DNA; SERUM AMYLOID P-COMPONENT;

EID: 84880125774     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1300269     Document Type: Article

References (68)

1. Ricklin, D., G. Hajishengallis, K. Yang, and J. D. Lambris. 2010. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol. 11: 785-797.
2. Zipfel, P. F., S. Heinen, M. Józsi, and C. Skerka. 2006. Complement and diseases: defective alternative pathway control results in kidney and eye diseases. Mol. Immunol. 43: 97-106. (Pubitemid 41021526)
3. Roumenina, L. T., C. Loirat, M.-A. Dragon-Durey, L. Halbwachs-Mecarelli, C. Sautes-Fridman, and V. Fremeaux-Bacchi. 2011. Alternative complement pathway assessment in patients with atypical HUS. J. Immunol. Methods 365: 8-26.
4. Fakhouri, F., V. Frémeaux-Bacchi, L. H. Noël, H. T. Cook, and M. C. Pickering. 2010. C3 glomerulopathy: a new classification. Nat. Rev. Nephrol. 6: 494-499.
5. de Cordoba, S. R., A. Tortajada, C. L. Harris, and B. P. Morgan. 2012. Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology 217: 1034-1046.
6. Ricklin, D., and J. D. Lambris. 2007. Complement-targeted therapeutics. Nat. Biotechnol. 25: 1265-1275. (Pubitemid 350089828)
7. Ferreira, V. P., M. K. Pangburn, and C. Cortés. 2010. Complement control protein factor H: the good, the bad, and the inadequate. Mol. Immunol. 47: 2187-2197.
8. Dinasarapu, A. R., A. Chandrasekhar, M. Józsi, and S. Subramaniam. 2012. Complement factor H. UCSD Molecule Pages 1: 71-86.
9. Hakobyan, S., C. L. Harris, A. Tortajada, E. Goicochea de Jorge, A. García-Layana, P. Fernández-Robredo, S. Rodríguez de Córdoba, and B. P. Morgan. 2008. Measurement of factor H variants in plasma using variant-specific monoclonal antibodies: application to assessing risk of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 49: 1983-1990.
10. Józsi, M., and P. F. Zipfel. 2008. Factor H family proteins and human diseases. Trends Immunol. 29: 380-387.
11. Boon, C. J., N. C. van de Kar, B. J. Klevering, J. E. Keunen, F. P. Cremers, C. C. Klaver, C. B. Hoyng, M. R. Daha, and A. I. den Hollander. 2009. The spectrum of phenotypes caused by variants in the CFH gene. Mol. Immunol. 46: 1573-1594.
12. Servais, A., L. H. Noël, L. T. Roumenina, M. Le Quintrec, S. Ngo, M.-A. Dragon-Durey, M. A. Macher, J. Zuber, A. Karras, F. Provot, et al. 2012. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82: 454-464.
13. Gordon, D. L., R. M. Kaufman, T. K. Blackmore, J. Kwong, and D. M. Lublin. 1995. Identification of complement regulatory domains in human factor H. J. Immunol. 155: 348-356.
14. Kühn, S., and P. F. Zipfel. 1996. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur. J. Immunol. 26: 2383-2387. (Pubitemid 26340939)
15. Wu, J., Y. Q. Wu, D. Ricklin, B. J. Janssen, J. D. Lambris, and P. Gros. 2009. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 10: 728-733.
16. Roversi, P., S. Johnson, J. J. Caesar, F. McLean, K. J. Leath, S. A. Tsiftsoglou, B. P. Morgan, C. L. Harris, R. B. Sim, and S. M. Lea. 2011. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc. Natl. Acad. Sci. USA 108: 12839-12844.
17. Ferreira, V. P., A. P. Herbert, H. G. Hocking, P. N. Barlow, and M. K. Pangburn. 2006. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J. Immunol. 177: 6308-6316. (Pubitemid 44628849)
18. Józsi, M., M. Oppermann, J. D. Lambris, and P. F. Zipfel. 2007. The C-terminus of complement factor H is essential for host cell protection. Mol. Immunol. 44: 2697-2706. (Pubitemid 46240314)
19. Kajander, T., M. J. Lehtinen, S. Hyvärinen, A. Bhattacharjee, E. Leung, D. E. Isenman, S. Meri, A. Goldman, and T. S. Jokiranta. 2011. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc. Natl. Acad. Sci. USA 108: 2897-2902.
20. Morgan, H. P., C. Q. Schmidt, M. Guariento, B. S. Blaum, D. Gillespie, A. P. Herbert, D. Kavanagh, H. D. Mertens, D. I. Svergun, C. M. Johansson, et al. 2011. Structural basis for engagement by complement factor H of C3b on a self surface. Nat. Struct. Mol. Biol. 18: 463-470.
21. Aslam, M., and S. J. Perkins. 2001. Folded-back solution structure of monomeric factor H of human complement by synchrotron X-ray and neutron scattering, analytical ultracentrifugation and constrained molecular modelling. J. Mol. Biol. 309: 1117-1138. (Pubitemid 32623312)
22. Fakhouri, F., E. G. de Jorge, F. Brune, P. Azam, H. T. Cook, and M. C. Pickering. 2010. Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int. 78: 279-286.
23. Sánchez-Corral, P., C. González-Rubio, S. Rodríguez de Córdoba and M. López-Trascasa. 2004. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol. Immunol. 41: 81-84. (Pubitemid 38609399)
24. Roumenina, L. T., M. Frimat, E. C. Miller, F. Provot, M.-A. Dragon-Durey, P. Bordereau, S. Bigot, C. Hue, S. C. Satchell, P. W. Mathieson, et al. 2012. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 119: 4182-4191.
25. Józsi, M., S. Strobel, H. M. Dahse, W. S. Liu, P. F. Hoyer, M. Oppermann, C. Skerka, and P. F. Zipfel. 2007. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110: 1516-1518. (Pubitemid 47443967)
26. Fridkis-Hareli, M., M. Storek, I. Mazsaroff, A. M. Risitano, A. S. Lundberg, C. J. Horvath, and V. M. Holers. 2011. Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases. Blood 118: 4705-4713.
27. Kühn, S., and P. F. Zipfel. 1995. The baculovirus expression vector pBSV-8His directs secretion of histidine-tagged proteins. Gene 162: 225-229.
28. Castiblanco-Valencia, M. M., T. R. Fraga, L. B. Silva, D. Monaris, P. A. Abreu, S. Strobel, M. Józsi, L. Isaac, and A. S. Barbosa. 2012. Leptospiral immunoglobulin-like proteins interact with human complement regulators factor H, FHL-1, FHR-1, and C4BP. J. Infect. Dis. 205: 995-1004.
29. Sánchez-Corral, P., D. Pérez-Caballero, O. Huarte, A. M. Simckes, E. Goicoechea, M. López-Trascasa, and S. R. de Córdoba. 2002. Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 71: 1285-1295. (Pubitemid 36015883)
30. Thiele, G. M., L. W. Klassen, and D. J. Tuma. 2008. Formation and immunological properties of aldehyde-derived protein adducts following alcohol consumption. Methods Mol. Biol. 447: 235-257.
31. Ishii, T., S. Kumazawa, T. Sakurai, T. Nakayama, and K. Uchida. 2006. Mass spectroscopic characterization of protein modification by malondialdehyde. Chem. Res. Toxicol. 19: 122-129. (Pubitemid 43185470)
32. Koistinen, V., S. Wessberg, and J. Leikola. 1989. Common binding region of complement factors B, H and CR1 on C3b revealed by monoclonal anti-C3d. Complement Inflamm. 6: 270-280. (Pubitemid 19181600)
33. Jokiranta, T. S., P. F. Zipfel, J. Hakulinen, S. Kühn, M. K. Pangburn, J. D. Tamerius, and S. Meri. 1996. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett. 393: 297-302. (Pubitemid 26298114)
34. Hebecker, M., and M. Józsi. 2012. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein. J. Biol. Chem. 287: 19528-19536.
35. Strobel, S., C. Abarrategui-Garrido, E. Fariza-Requejo, H. Seeberger, P. Sánchez-Corral, and M. Józsi. 2011. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int. 80: 397-404.
36. Strobel, S., P. F. Hoyer, C. J. Mache, E. Sulyok, W. S. Liu, H. Richter, M. Oppermann, P. F. Zipfel, and M. Józsi. 2010. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 25: 136-144.
37. Jokiranta, T. S., J. Hellwage, V. Koistinen, P. F. Zipfel, and S. Meri. 2000. Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J. Biol. Chem. 275: 27657-27662.
38. Schmidt, C. Q., A. P. Herbert, D. Kavanagh, C. Gandy, C. J. Fenton, B. S. Blaum, M. Lyon, D. Uhrín, and P. N. Barlow. 2008. A new map of glycosaminoglycan and C3b binding sites on factor H. J. Immunol. 181: 2610-2619.
39. Jarva, H., T. S. Jokiranta, J. Hellwage, P. F. Zipfel, and S. Meri. 1999. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J. Immunol. 163: 3957-3962. (Pubitemid 29450924)
40. Deban, L., H. Jarva, M. J. Lehtinen, B. Bottazzi, A. Bastone, A. Doni, T. S. Jokiranta, A. Mantovani, and S. Meri. 2008. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J. Immunol. 181: 8433-8440.
41. Mihlan, M., S. Stippa, M. Józsi, and P. F. Zipfel. 2009. Monomeric CRP contributes to complement control in fluid phase and on cellular surfaces and increases phagocytosis by recruiting factor H. Cell Death Differ. 16: 1630-1640.
42. Okemefuna, A. I., R. Nan, A. Miller, J. Gor, and S. J. Perkins. 2010. Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations. J. Biol. Chem. 285: 1053-1065.
43. Kopp, A., S. Strobel, A. Tortajada, S. Rodríguez de Córdoba, P. Sánchez-Corral, Z. Prohászka, M. López-Trascasa, and M. Józsi. 2012. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3. J. Immunol. 189: 1858-1867.
44. Weismann, D., K. Hartvigsen, N. Lauer, K. L. Bennett, H. P. Scholl, P. Charbel Issa, M. Cano, H. Brandstätter, S. Tsimikas, C. Skerka, et al. 2011. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478: 76-81.
45. Oppermann, M., T. Manuelian, M. Józsi, E. Brandt, T. S. Jokiranta, S. Heinen, S. Meri, C. Skerka, O. Götze, and P. F. Zipfel. 2006. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin. Exp. Immunol. 144: 342-352.
46. Józsi, M., C. Licht, S. Strobel, S. L. Zipfel, H. Richter, S. Heinen, P. F. Zipfel, and C. Skerka. 2008. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111: 1512-1514. (Pubitemid 351213440)
47. Blanc, C., L. T. Roumenina, Y. Ashraf, S. Hyvärinen, S. K. Sethi, B. Ranchin, P. Niaudet, C. Loirat, A. Gulati, A. Bagga, et al. 2012. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J. Immunol. 189: 3528-3537.
48. Noris, M., and G. Remuzzi. 2008. Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clin. Exp. Immunol. 151: 199-209.
49. Schmidt, C. Q., F. C. Slingsby, A. Richards, and P. N. Barlow. 2011. Production of biologically active complement factor H in therapeutically useful quantities. Protein Expr. Purif. 76: 254-263.
50. Büttner-Mainik, A., J. Parsons, H. Jérôme, A. Hartmann, S. Lamer, A. Schaaf, A. Schlosser, P. F. Zipfel, R. Reski, and E. L. Decker. 2011. Production of biologically active recombinant human factor H in Physcomitrella. Plant Biotechnol. J. 9: 373-383.
51. Perkins, S. J., R. Nan, K. Li, S. Khan, and A. Miller. 2012. Complement factor H-ligand interactions: self-association, multivalency and dissociation constants. Immunobiology 217: 281-297.
52. Laine, M., H. Jarva, S. Seitsonen, K. Haapasalo, M. J. Lehtinen, N. Lindeman, D. H. Anderson, P. T. Johnson, I. Järvelä, T. S. Jokiranta, et al. 2007. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J. Immunol. 178: 3831-3836. (Pubitemid 46417652)
53. Skerka, C., N. Lauer, A. A. Weinberger, C. N. Keilhauer, J. Sühnel, R. Smith, U. Schlötzer-Schrehardt, L. Fritsche, S. Heinen, A. Hartmann, et al. 2007. Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol. Immunol. 44: 3398-3406. (Pubitemid 46678196)
54. Lauer, N., M. Mihlan, A. Hartmann, U. Schlötzer-Schrehardt, C. Keilhauer, H. P. Scholl, P. Charbel Issa, F. Holz, B. H. Weber, C. Skerka, and P. F. Zipfel. 2011. Complement regulation at necrotic cell lesions is impaired by the age-related macular degeneration-associated factor-H His402 risk variant. J. Immunol. 187: 4374-4383.
55. Clark, S. J., L. A. Ridge, A. P. Herbert, S. Hakobyan, B. Mulloy, R. Lennon, R. Würzner, B. P. Morgan, D. Uhrín, P. N. Bishop, and A. J. Day. 2013. Tissue-specific host recognition by complement factor H is mediated by differential activities of its glycosaminoglycan-binding regions. J. Immunol. 190: 2049-2057.
56. Jokiranta, T. S., A. Solomon, M. K. Pangburn, P. F. Zipfel, and S. Meri. 1999. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J. Immunol. 163: 4590-4596. (Pubitemid 29474530)
57. Nozal, P., S. Strobel, M. Ibernon, D. López, P. Sánchez-Corral, S. Rodríguez de Córdoba, M. Józsi, and M. López-Trascasa. 2012. Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clin. Kidney J. 5: 133-136.
58. Goodship, T. H., I. Y. Pappworth, T. Toth, M. Denton, K. Houlberg, F. McCormick, D. Warland, I. Moore, E. M. Hunze, S. J. Staniforth, et al. 2012. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol. Immunol. 52: 200-206.
59. Meri, S. 2007. Loss of self-control in the complement system and innate autoreactivity. Ann. N. Y. Acad. Sci. 1109: 93-105. (Pubitemid 47511348)
60. Zipfel, P. F., and N. Lauer. 2013. Defective complement action and control defines disease pathology for retinal and renal disorders and provides a basis for new therapeutic approaches. Adv. Exp. Med. Biol. 735: 173-187.
61. Goicoechea de Jorge, E., C. L. Harris, J. Esparza-Gordillo, L. Carreras, E. A. Arranz, C. A. Garrido, M. López-Trascasa, P. Sánchez-Corral, B. P. Morgan, and S. Rodríguez de Córdoba. 2007. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. USA 104: 240-245. (Pubitemid 46068016)
62. Roumenina, L. T., M. Jablonski, C. Hue, J. Blouin, J. D. Dimitrov, M. A. Dragon-Durey, M. Cayla, W. H. Fridman, M. A. Macher, D. Ribes, et al. 2009. Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood 114: 2837-2845.
63. Martínez-Barricarte, R., M. Heurich, F. Valdes-Cañedo, E. Vazquez-Martul, E. Torreira, T. Montes, A. Tortajada, S. Pinto, M. Lopez-Trascasa, B. P. Morgan, et al. 2010. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J. Clin. Invest. 120: 3702-3712.
64. Sartz, L., A. I. Olin, A. C. Kristoffersson, A. L. Stähl, M. E. Johansson, K. Westman, V. Fremeaux-Bacchi, K. Nilsson-Ekdahl, and D. Karpman. 2012. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J. Immunol. 188: 2030-2037.
65. Paixão-Cavalcante, D., M. López-Trascasa, L. Skattum, P. C. Giclas, T. H. Goodship, S. R. de Córdoba, L. Truedsson, B. P. Morgan, and C. L. Harris. 2012. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation. Kidney Int. 82: 1084-1092.
66. Risitano, A. M. 2012. Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders. Immunobiology 217: 1080-1087.
67. Ferreira, V. P., and M. K. Pangburn. 2007. Factor H mediated cell surface protection from complement is critical for the survival of PNH erythrocytes. Blood 110: 2190-2192. (Pubitemid 47443939)
68. Risitano, A. M., R. Notaro, C. Pascariello, M. Sica, L. del Vecchio, C. J. Horvath, M. Fridkis-Hareli, C. Selleri, M. A. Lindorfer, R. P. Taylor, et al. 2012. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment. Blood 119: 6307-6316.